Patents Examined by Lia E Taylor
  • Patent number: 11186617
    Abstract: The present invention relates to a polypeptide comprising an epitope of an antigen; a kit and a composition for diagnosing allergy, wherein the kit and the composition comprise the aforementioned polypeptide, and a method for diagnosing allergy and a method for treating allergy, wherein the methods use the aforementioned polypeptide; a pharmaceutical composition comprising the aforementioned polypeptide; and a raw material or a processed product in which the antigen comprising the aforementioned polypeptide is removed or reduced. Furthermore, the present invention relates to a tester for determining the presence or absence of the antigen in an object.
    Type: Grant
    Filed: December 18, 2018
    Date of Patent: November 30, 2021
    Assignee: HOYU CO., LTD.
    Inventors: Yuji Aoki, Fumiaki Ono
  • Patent number: 11161910
    Abstract: The present invention provides glycated Amadori products of the CD59 peptide and fragments thereof to be used as tools and among methods for the diagnosis and prognosis of pre-diabetes and diabetes. Certain aspects of the invention include glycated Amadori products of CD59 and fragments thereof to be used for the generation of antibodies and antibody fragments. Still other aspects of the invention include methodologies for the preparation of glycated Amadori products of CD59, fragments thereof, the inventive antibodies, and antibody fragments.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: November 2, 2021
    Assignee: President and Fellows of Harvard College
    Inventors: Jose A. Halperin, Michael Chorev
  • Patent number: 11155638
    Abstract: The present disclosure relates to antibodies that bind human chitinase-3-like protein 1 (CHI3L1) and uses thereof. In aspects, the antibodies are useful in compositions and methods for detecting and/or treating nonalcoholic steatohepatitis (NAFLD) or nonalcoholic fatty liver disease (NASH) in a subject, as well as subsequent complications of untreated progression in the liver of a subject, such as liver cirrhosis and/or a hepatocellular carcinoma.
    Type: Grant
    Filed: May 7, 2019
    Date of Patent: October 26, 2021
    Assignee: RHODE ISLAND HOSPITAL
    Inventors: Jack R. Wands, Rolf I. Carlson
  • Patent number: 11155637
    Abstract: This invention relates to isolated antibodies which recognize the exosite 1 epitope of thrombin and selectively inhibit thrombin without promoting bleeding. These antibody molecules may be useful in the treatment and prevention of thrombosis, embolism and other conditions mediated by thrombin.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: October 26, 2021
    Assignee: Janssen Pharmaceuticals, Inc.
    Inventors: James Andrew Huntington, Trevor Baglin, Jonathan Langdown
  • Patent number: 11124572
    Abstract: The present disclosure provides isolated binding molecules that bind to and blocks PD-L1, vectors comprising a nucleic acid molecules encoding an amino acid sequence of the binding molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring stimulation of immune responses including cancer.
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: September 21, 2021
    Assignee: QLSF BIOTHERAPEUTICS INC.
    Inventor: Shihao Chen
  • Patent number: 11104718
    Abstract: Targeted Factor VIII molecules comprising a Factor VIII linked with at least one domain that specifically binds to a membrane protein on a red blood cell is provided. The disclosed targeted coagulation factors prolong their duration of action and thus, are an improvement for the treatment of hematological diseases such as hemophilia A.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: August 31, 2021
    Assignee: Bayer HealthCare LLC
    Inventors: Alan Brooks, Richard Feldman, Jian-Ming Gu, Shaun Lippow, Shujun Yuan, Peter Bringmann
  • Patent number: 11098132
    Abstract: Provided herein are anti-Factor IX Padua binding constructs, e.g., antibodies and antigen-binding fragments thereof. Related polypeptides, conjugates and kits are also provided. The inventions may be used in methods of detecting Factor IX Padua in a sample.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: August 24, 2021
    Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED
    Inventors: Dirk Voelkel, Robert Pachlinger, Hanspeter Rottensteiner, Alfred Weber, Andrea Engelmaier
  • Patent number: 11078276
    Abstract: The present disclosure provides humanized and affinity matured antibodies (mAbs) and fragments thereof that specifically bind to CD79 with high affinity. The anti-CD79 mAbs and fragments thereof can be used to treat antibody-associated conditions, including autoimmune diseases, allergies, transplant rejection, or immune-mediated rejection of a therapeutics optionally in combination with an additional therapeutic agent. Furthermore, the anti-CD79 mAbs and fragments thereof can be used for diagnostic purposes, including to detect CD79 cells in biological samples and to diagnose B-cell associated disorders.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: August 3, 2021
    Assignee: Nepenthe Bioscience LLC
    Inventors: James Larrick, Bo Yu, Andrew Mendelsohn, John C. Cambier
  • Patent number: 11028176
    Abstract: The present disclosure provides, inter alia, anti-peripheral lymph node addressin antibodies and antigen binding fragments thereof. The present disclosure also provides compositions comprising drug-containing polymeric particles that mimic lymphocyte migration in vivo and can specifically deliver immunosuppressive or immunoregulatory drugs to lymphoid tissues and sites of chronic inflammation where T-cell activation and T-cell mediated injury are occurring; such compositions comprise the antibodies or antigen-binding fragments thereof described in the disclosure. The present disclosure also comprises antibody-drug conjugates and compositions comprising the antibody-drug conjugates. Methods of preparing and using these antibodies, antigen-binding fragments thereof, and compositions thereof are also provided.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: June 8, 2021
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Reza Abdi